Cellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Br...
23 Juni 2016 - 2:30PM
Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"), an
oncology-focused biotechnology company, today announces the results
of the first phase of a National Cancer Institute (NCI)-funded
Small Business Innovation Research (SBIR) Phase 1 contract for a
study of CLR 125, a radiotherapeutic isotope, which may be uniquely
suited to treat micro-metastatic disease, conjugated to the
company’s proprietary phospholipid drug conjugate (PDC) delivery
platform.
The study demonstrated that a single dose of CLR 125 reduced the
volume of human-derived primary triple negative breast cancer
xenografts (tumor models) by approximately 60 percent, compared to
a control vehicle (p<0.001), as well as significantly extending
survival. CLR 125 also significantly weakened the progression
of micrometastases (p< 0.01) and reduced established metastases
(p< 0.01) compared to the control vehicle. Importantly,
within 96 hours of dosing, investigators observed that
radioactivity cleared from subjects’ blood and organs and
accumulated primarily in the tumor cells where it was retained past
144 hours.
“These study results provide further validation of the benefits
of our Phospholipid Drug Conjugate (PDC) development program,
whether in cytotoxics, as in our previously announced paclitaxel
program or radiotherapeutics, as this study demonstrated,” said Jim
Caruso, president and CEO of Cellectar Biosciences. “Further,
these data clearly show that our PDC delivery platform may possess
clinical utility in a broad range of cancer types with a wide
variety of cytotoxic compounds.”
This trial represents the first phase of the SBIR contract for a
Phase 1 study sponsored by NCI. Following a complete review
of the data, an assessment of potential clinical applications, and
differentiated product benefits, both NCI and the company will
determine whether to advance CLR 125 into phase 2 of the
contract.
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC Delivery Platform is based on the company's
proprietary phospholipid ether analogs. These novel
small-molecules have demonstrated highly selective uptake and
retention in a broad range of cancers. Cellectar's PDC
pipeline includes product candidates for cancer therapy and cancer
diagnostic imaging. The company's lead therapeutic PDC, CLR
131, utilizes iodine-131, a cytotoxic radioisotope, as its payload.
CLR 131 is currently being evaluated under an orphan drug
designated Phase 1 study in patients with relapsed or refractory
multiple myeloma. The company is actively developing PDCs for
targeted delivery of chemotherapeutics such as paclitaxel (CLR
1602-PTX), a preclinical stage product candidate, and plans to
expand its PDC chemotherapeutic pipeline through both in-house and
collaborative R&D efforts. For additional information please
visit www.cellectarbiosciences.com
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current
beliefs and expectations as to such future outcomes. Drug
discovery and development involve a high degree of risk.
Factors that might cause such a material difference include,
among others, uncertainties related to the ability to raise
additional capital, uncertainties related to the ability to attract
and retain partners for our technologies, the identification of
lead compounds, the successful preclinical development thereof, the
completion of clinical trials, the FDA review process and other
government regulation, our pharmaceutical collaborators' ability to
successfully develop and commercialize drug candidates, competition
from other pharmaceutical companies, product pricing and
third-party reimbursement. A complete description of risks
and uncertainties related to our business is contained in our
periodic reports filed with the Securities and Exchange Commission,
including our Form 10-K for the year ended December 31, 2015.
These forward-looking statements are made only as of the date
hereof, and we disclaim any obligation to update any such
forward-looking statements.
CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
INVESTOR CONTACT:
Stephanie Prince
Managing Director
PCG Advisory Group
646-762-4518
sprince@pcgadvisory.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024